drugset / Trial / NCT01510626

Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

NCT01510626

Phase 1 Completed 35 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies. The investigators hypothesize that the application of this protocol will allow patients with severe and single or multiple food allergies to be safely and rapidly desensitized.

Timeline

Start
2011-11
Primary completion
2014-04
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody